Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives $55.00 Consensus Price Target from Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have received a consensus recommendation of “Buy” from the eighteen ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $55.00.

Several research analysts recently weighed in on the stock. Robert W. Baird boosted their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Wells Fargo & Company assumed coverage on Definium Therapeutics in a report on Monday, July 27th. They issued an “overweight” rating and a $68.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Canaccord Genuity Group set a $58.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, JonesTrading upped their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, June 24th.

Insider Transactions at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares in the company, valued at $9,433,199.61. The trade was a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 48,096 shares of company stock valued at $2,165,763. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Definium Therapeutics in the 4th quarter valued at $117,000. Caxton Associates LLP acquired a new position in shares of Definium Therapeutics during the 3rd quarter valued at $126,000. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in shares of Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares in the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $45.15 on Friday. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70. The company has a market capitalization of $4.50 billion, a P/E ratio of -13.16 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $38.32 and a two-hundred day moving average price of $26.16.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, research analysts expect that Definium Therapeutics will post -2.27 earnings per share for the current fiscal year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.